Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 25, 2018

Primary Completion Date

December 24, 2021

Study Completion Date

April 11, 2022

Conditions
Behcet's DiseaseVasculitis
Interventions
DRUG

Infliximab

Use of infliximab instead of cyclophosphamide

DRUG

Cyclophosphamide

Use of cyclophosphamide

Trial Locations (27)

Unknown

CHRU Amiens, Amiens

Hôpital Avicenne, Bobigny

CHU Bordeaux, Bordeaux

Hôpital Saint André, Bordeaux

CH Ambroise Paré, Boulogne-Billancourt

CHU Caen, Caen

Henri Mondor Hospital, Créteil

CHU Dijon, Dijon

CHU Grenoble, Grenoble

CHU Bicêtre, Le Kremlin-Bicêtre

CHRU Lille, Lille

Hôpital de la Croix Rousse, Lyon

Hôpital Edouard Herriot, Lyon

Hôpital de La Timone, Marseille

CH Metz, Metz

CHU Bichat, Paris

CHU Tenon, Paris

Hôpital de La Pitié Salpetriere, Paris

Hôpital Foch, Paris

Hôpital Lariboisière, Paris

Hôpital Saint Antoine, Paris

Hôpital Saint Louis, Paris

CHU Poitiers, Poitiers

Hôpital Bois Guillaume, Rouen

CH Saint-Denis, Saint-Denis

CHU Purpan, Toulouse

CH Valenciennes, Valenciennes

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03371095 - Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease | Biotech Hunter | Biotech Hunter